Theravance Biopharma, Inc.
The company is engaged in the development and commercialization of drugs to treat respiratory and digestive diseases. Rebefenacin, a once-daily bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD), is in development as a potential treatment for various inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Cayman Islands registered
Overview
Overview | |
|---|---|
Country | Cayman Islands |
State | |
Employees | 99 |
Founded | |
Financials | |
|---|---|
Market Capitalization | 455.69M |
Revenue | 61.51M |
Operating Income | -42.33M |
Operating Margin | -68.82% |
Net Income | -44.77M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4362 / 5373 |
Sector : Healthcare | 678 / 1144 |
Industry : Biotechnology | 304 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3065 / 5565 |
Sector : Healthcare | 462 / 1182 |
Industry : Biotechnology | 220 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4270 / 5436 |
Sector : Healthcare | 680 / 1164 |
Industry : Biotechnology | 317 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4040 / 5330 |
Sector : Healthcare | 645 / 1174 |
Industry : Biotechnology | 260 / 667 |